0243 GMT - Breathing-tech provider ResMed doesn't get enough credit from the market for its operational cost control, UBS analyst Laura Sutcliffe reckons. Dual-listed ResMed is scheduled to report its December-quarter financials at the end of January and Sutcliffe thinks its core operating profit will come in about 2% ahead of the average analyst forecast. This is even though her revenue forecast is in line with average expectations. As for U.S. device sales, she tells clients in a note that app downloads suggest that its market share remains steady above 80%. UBS raises its target price on ResMed's U.S.-listed securities by 2% to US$255.00. The stock closed 0.2% lower at US$247.33. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
January 22, 2025 21:43 ET (02:43 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。